sponsored
PatientsVille.com Logo

PatientsVille

Cordis Medical Research Studies

Up-to-date List of Cordis Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Cordis Medical Research Studies

Rank Status Study
1 Unknown  Optical Coherence Tomography for Drug Eluting Stent Safety
Condition: Coronary Artery Disease
Interventions: Device: sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co);   Device: paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS);   Device: zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA);   Device: Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)
Outcome Measures: Number of uncovered and/or malapposed stent struts at overlapping versus non overlapping sites in drug eluting vs bare metal stents;   Ischemia Driven Target Vessel Failure;   Number of uncovered and/or malapposed stent struts at overlapping sites in sirolimus-, paclitaxel- or zotarolimus eluting stents
2 Unknown  Renal Stenting With Distal Atheroembolic Protection
Conditions: Renal Artery Obstruction;   Renovascular Hypertension
Interventions: Procedure: Percutaneous renal stenting intervention;   Device: Distal embolic protection
Outcome Measures: Differences in renal function loss (measured as Cr clearance and/or cystatin C) after 1 and 3 months of follow-up;   Acute complications, especially atheroembolism;   Evaluations of the covariates associated with a better outcome in the atheroembolic device group;   Blood pressure control (number of medication needed to keep BP<140/90 )
3 Recruiting SAPPHIRE Worldwide: Stenting and Angioplasty With Protection in Patients At High-Risk for Endarterectomy
Condition: Carotid Artery Disease
Intervention:
Outcome Measures: Any death, stroke or any MI;   Assess the consistency of MAE rates of stenting with distal protection in the treatment of obstructive carotid artery disease among high, medium and low volume centers with physicians who have validated CASES training levels of 1, 2, 2P or 3;   Assess the real-world cost-effectiveness of carotid artery stenting in subjects enrolled;   Estimate MAE (death and ipsilateral stroke) rate in a subset of the planned total enrollment
4 Unknown  Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction
Condition: Myocardial Infarction
Interventions: Genetic: Allogeneic Mesenchymal Precursor Cells (MPCs);   Procedure: Standard-of-care treatment with NOGA® mapping and staged injections.
Outcome Measures: Evaluate the safety and feasibility of transendocardial injection using the Cordis Biosense NogaStarTM Mapping Catheter with the Biosense MyostarTM Left Ventricular Injection Catheter of allogeneic mesenchymal precursor cells (MPCs) in subjects with AMI.;   Explore efficacy for subsequent study design and dose related tolerance: •Effect related to cardiac function.•Change from baseline in SF-36, KCCQ, SAQ, and the NYHA Classification.•Follow-up safety through Day 360 • Dose selection for future stu
5 Recruiting Intramyocardial Multiple Precision Injection of Bone Marrow Mononuclear Cells in Myocardial Ischemia
Condition: Heart Failure
Intervention: Procedure: NOGA XP Cardiac Navigation System
Outcome Measures: Change in global left ventricular ejection fraction and regional wall motion score index;   Incidence of the major adverse cardiac events
6 Recruiting Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease
Condition: Peripheral Vascular Diseases
Interventions: Device: Stenting (Smart Stent);   Device: Stenting after PEB (Smart Stent, Invatec);   Procedure: Atherectomy (SilverHawk device)
Outcome Measures: Percentage diameter stenosis;   All-cause mortality;   Major adverse peripheral events (MAPE) defined as acute thrombosis of SFA or ipsilateral amputation or revascularization (PTA or bypass surgery);   Time to onset of any of MAPE.;   Binary restenosis rate;   Percentage diameter stenosis in duplex ultrasound;   Change from baseline in functional status and health related quality of life (Walking Impairment Questionaire)
7 Recruiting Comparing Carotid Stenting With Endarterectomy in Severe Asymptomatic Carotid Stenosis
Condition: Carotid Stenosis
Interventions: Procedure: carotid artery stenting;   Procedure: carotid endarterectomy
Outcome Measures: comparison of cardiovascular mortality and morbidity which includes cardiac and neurological morbidity (TIA and CVA) in the two invasive treatments of asymptomatic carotid artery stenosis;   incision site morbidity;   cranial nerves damage;   brain hyperperfusion;   bradycardia within the first 24 hours;   microembolic brain events;   long term recurrence;   effect on patient life style
8 Unknown  Stenting With or Without Coating Compared With Angioplasty in Non-benestent Disease
Condition: Coronary Artery Disease
Intervention: Device: Bx Sonic & Cypher stent from Cordis
Outcome Measure:
9 Recruiting Incidence and Prognostic Value of DELIRIUM in Patients With Acute CORonary synDrome: an observatIonal Study
Conditions: Delirium;   Acute Coronary Syndrome
Intervention:
Outcome Measures: in-hospital adverse events incidence;   12-month adverse events incidence
10 Recruiting Serial EValuation of multiplE Coronary Artery Diseases by an Optical Coherence Tomography; Assessment of the Changes of de Novo Lesions and Comparisons of Neointimal Coverage Between Xience Prime® Versus Cypher SelectTM Stents; SEVEN-Xience Study
Condition: Multi-vessel Diseases, Angina
Interventions: Device: Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL);   Device: Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA);   Drug: Pravastatin 20mg;   Drug: Atorvastatin 40mg
Outcome Measure: neointimal coverage according to the implanted DES; Xience vs. Cypher
11 Not yet recruiting Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study)
Condition: Renal Artery Stenosis
Interventions: Drug: Optimal medical therapy;   Procedure: revascularization
Outcome Measures: Glomerular filtration rate in the ischemic kidney after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.;   Lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.;   Preserving overall renal function after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.;   Regression of damage in the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.
12 Available Compassionate Use of the Incraft® AAA Stent Graft System
Condition: Abdominal Aortic Aneurysm
Intervention: Device: Endovascular AAA repair
Outcome Measure:
13 Recruiting Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
Conditions: Coronary Artery Disease;   Coronary Disease;   Coronary Stenosis
Intervention: Device: Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
Outcome Measures: In-segment late luminal loss at 9 months as assessed by an independent angiographic core lab.;   In-stent late luminal loss;   In-stent and in-segment binary restenosis rate;   In-stent and in-segment minimal lumen diameter;   Percentage diameter stenosis;   A composite of major adverse cardiac events (MACE: death, myocardial infarction and clinically driven target lesion revascularization);   Stent thrombosis (acute, <1day; subacute, 1 to 30 days; and late, >30 days);   Target vessel failure (cardiac death, MI, clinically driven target vessel revascularisation) up to 5 year of clinical follow-up.;   % of uncovered stent struts, % of malapposed stent struts, tissue strut thickness (µm), absolute volume (mm³) and % of intimal hyperplasia
14 Recruiting Angio-Seal® vs. Exo-Seal® for Closure of Arterial Puncture Sites
Conditions: Acute Coronary Syndromes;   Stable Angina Pectoris
Intervention: Device: percutaneous coronary intervention
Outcome Measures: bleeding, need for vascular surgery and device failure;   occurance of false aneurysms, severe pain (Borg ≥ 5), and hematoma ≥ 5 cm within 24 hours after insertion of the device.
15 Recruiting Evaluation of Safety and Efficacy of the FlexStent® Femoropopliteal Self-Expanding Stent System
Conditions: Peripheral Artery Disease;   Peripheral Vascular Disease;   Vascular Disease;   Cardiovascular Diseases;   PAD
Intervention: Device: FlexStent® Femoropopliteal Self Expanding Stent System
Outcome Measures: The primary safety endpoint will be a composite of all death, TLR, or index limb amputation.;   The primary efficacy endpoint will be vessel patency at 12 months, defined as freedom from greater than 50% restenosis.
16 Unknown  Relationship Between Abnormalities of Desmin Cytoskeleton, Mitochondrial Activity and Expression of Ubiquitin in Aspect of Pathogenesis of Heart Failure and Prognosis
Condition: Dilated Cardiomyopathy
Intervention: Procedure: cardiobiopsy
Outcome Measures: all cause mortality;   qualitative differences in desmin expression in cardiomyocytes of patient with heart failure
17 Unknown  Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for DES Surface COVERage by OCT
Conditions: Coronary Heart Disease;   Diabetes Mellitus
Intervention: Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)
Outcome Measures: Comparison of the surface coverage between DM and Non-DM at 6 months after Cypher and YINYI stent implantation using OCT.;   Comparison of troponin-I levels between DM and Non-DM at baseline, 8 hours, 16 hours and 24 hours after stent implantation;   Comparison of hsCRP concentration between DM and Non-DM at baseline, 8 hours, 16 hours and 24 hours after stent implantation;   Comparison of the malapposition, neointimal heterogeneity and the incidence of thrombosis between DM and Non-DM patients after Cypher and YINYI implantation using OCT;   Comparison of surface coverage, late stent malapposition, neointimal heterogeneity and the incidence of thrombosis between Cypher and YINYI in DM after stenting using OCT;   Comparison of surface coverage, late stent malapposition, neointimal heterogeneity, and the incidence of thrombosis between Cypher and YINYI in Non-DM after stenting using OCT;   QCA parameters and IVUS parameters for binary restenosis, late lumen loss.;   Comparison of the surface coverage, late stent malapposition, neointimal heterogeneity, and the incidence of thrombosis between DM and Non-DM patients after Cypher and YINYI implantation using OCT;   Comparison of surface coverage, late stent malapposition, neointimal heterogeneity, and the incidence of thrombosis between Cypher and YINYI in DM after stenting using OCT;   TLR/TVR;   MACE
18 Recruiting Comparison Between Everolimus-eluting Stent (EES) and Sirolimus-eluting Stent (SES) in the Bifurcation Lesion
Condition: Ischemic Heart Disease
Interventions: Procedure: kissing balloon inflation;   Device: EES vs. SES
Outcome Measures: Major adverse cardiac events;   abnormal intimal coverage
19 Unknown  Treatment of Bifurcated Coronary Lesions With Cypher™-Stent
Condition: Coronary Artery Disease
Intervention: Procedure: PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique
Outcome Measures: In-segment percent diameter stenosis of the side branch at 9 months post procedure as measured by quantitative coronary angiography.;   Freedom from Major Adverse Cardiac Events (MACE)at 30 days, 6 and 12 months;   Angiographic binary restenosis (≥ 50% diameter stenosis) in the main and side branch at 9 months post procedure.;   Target Lesion Revascularization (TLR) at 12 months post procedure.;   Device success during PCI;   Post-procedure thrombotic stent occlusion at 12 months

These studies may lead to new treatments and are adding insight into Cordis etiology and treatment.

A major focus of Cordis research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Cordis